Section Arrow
TERN.NASDAQ
- Terns Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/07 08:11 EDT
Pre Market
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
52.95 
1-M High
52.98 
Volume 
-- 
Bid
--
Ask
--
Day Low
-- 
Open
-- 
1-M Low
52.42 
Market Cap 
-- 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 52.9 
20-SMA 52.78 
50-SMA 49.21 
52-W High 53.19 
52-W Low 2.655 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.03/-1.69
Enterprise Value
6.12B
Balance Sheet
Book Value Per Share
8.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
No related information.
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.